Welcome to LookChem.com Sign In|Join Free

CAS

  • or

610323-25-6

Post Buying Request

610323-25-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

610323-25-6 Usage

Chemical compound

2H-Benzimidazol-2-one, 1-[1-[(1R)-1,2-dihydro-1-acenaphthylenyl]-4-piperidinyl]-1,3-dihydro-

Properties

1. Complex organic molecule
2. Benzimidazole core
3. Piperidine side chain
4. Dihydro-derivative
5. Chiral with 1R configuration

Potential applications

1. Pharmaceutical compound
2. Possible interaction with neurological receptors
3. Modulation of neurotransmitter activity
Further research and analysis required for full understanding of properties and applications

Check Digit Verification of cas no

The CAS Registry Mumber 610323-25-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,1,0,3,2 and 3 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 610323-25:
(8*6)+(7*1)+(6*0)+(5*3)+(4*2)+(3*3)+(2*2)+(1*5)=96
96 % 10 = 6
So 610323-25-6 is a valid CAS Registry Number.

610323-25-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-[1-[(1R)-1,2-dihydroacenaphthylen-1-yl]piperidin-4-yl]-1H-benzimidazol-2-one

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:610323-25-6 SDS

610323-25-6Upstream product

610323-25-6Relevant articles and documents

REMEDY FOR SLEEP DISTURBANCE

-

Page 14, (2008/06/13)

The present invention has been made based on the finding that a compound acting on the ORL-1 receptor as an agonist acts as a non-photic entrainment factor, and advances the circadian rhythm phase, and provides a novel therapeutic agent for a sleep disorder such as circadian rhythm sleep disorder, more particularly, an agent for the prophylaxis and/or treatment of a sleep disorder, which contains an ORL-1 receptor agonist, and a novel compound useful as such agent for the prophylaxis and/or treatment.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 610323-25-6